All In Biotech

Drug Trial Radar · NCT06481475

A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar Lines

A Randomized Double-blind Vehicle-controlled Parallel-dose Phase II Study Evaluating the Safety and Efficacy of a Recombinant Botulinum Neurotoxin Type A Injection (YY003) for the Treatment of Moderate to Severe Glabellar Lines in Adults

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

153

Actual

Start

Jan 9, 2025

Primary completion

Oct 22, 2025

Study completion Dec 28, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a two-part (Part A and Part B) randomized double-blind vehicle-controlled multi-center study in a total of 174 participants with moderate to severe glabellar lines. The objective of this study is to test the safety, efficacy, immunogenicity of YY003, and compare to vehicel control, in improving the appearance of moderate to severe glabellar lines.

Conditions

  • Moderate to Severe Glabellar Lines

Interventions

  • YY003Biological

    Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.

  • Vehicle ControlBiological

    Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Satety: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESI), and serious adverse events (SAEs)Time frame: within 4 weeks post-treatment
  2. Efficacy: The proportion of participants achieving a score of 0 or 1 and at least a two-grade improvement from baseline, on both the investigator's assessment and the participant's self-assessmenti of glabellar line severity at maximum frownTime frame: at Week 4 post-treatment visit

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • St George Dermatology & Skin Cancer Centre

    Sydney, New South Wales, Australia

  • Skin Health Institute

    Melbourne, Victoria, Australia

  • Dermatology Institute of Victoria

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.